Global Migraine In-Depth Industrial and Market studies Report: 2017 Edition
Albany, New York, Mar 01, 2017
"Global
Migraine Market Report: 2017 Edition"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
Migraine
is a common neurovascular disorder that is characterized by throbbing
headaches and is commonly associated with other neurological
symptoms, such as nausea, vomiting, and painful sensitivity to lights
and sounds. Migraines are thought to result from the activation and
sensitization of sensory neurons that have nerve endings in meningeal
blood vessels. Migraines can be episodic or chronic. Chronic Migraine
(CM) and Episodic Migraine (EM) are both part of the spectrum of
migraine disorders, but are distinct clinical entities. The onset of
migraine is preceded by certain triggers, which can be unique for
each migraine sufferer.
Triptans
and Ergots are among the most common drug options existing in the
treatment market for migraine. The global migraine treatment market
currently faces several unmet needs and is saturated with the
availability of generic drugs. Several branded drugs are under
development with safer and more effective profiles, given the vast
opportunities existing in the market. The focus of upcoming drugs is
to either cure migraine or to reduce the frequency to a level where
patients can find tolerable relief.
The migraine market is expected to acquire modest
growth driven by launch of new therapies and increasing rate of drug
treatment due to increasing female population and rising awareness
among physicians and patients. The major growth drivers of the
migraine market includes rising spending on medicines, growing female
population, increasing cigarette consumption and healthcare
expenditure. However, the growth of the market will also remain
challenged by complications associated with Triptans, treatment
limitations for patients with CV (Cardio Vascular) risk and increased
preference for OTC (Over the Counter) medications.
The report, “Global Migraine Market” analyzes
the currently prevailing condition of the market along with its
future scope of development. The specific market of the U.S. is being
discussed in the report. The major trends, growth drivers as well as
issues being faced by the industry are being presented in this
report. The major players in the industry are being profiled, along
with their key financials and strategies for growth.
Table
of Content
1. Market Overview
1.1 Introduction
1.2 Types
1.3 Causes and Pathogenesis
1.4 Symptoms and Diagnosis
1.5 Treatment Options
1.1 Introduction
1.2 Types
1.3 Causes and Pathogenesis
1.4 Symptoms and Diagnosis
1.5 Treatment Options
2. Global Migraine Market
2.1 Global Migraine Drug Market by Value
2.2 Global Migraine Drug Market by Category
2.3 Global Therapeutic Botulinum Toxin Market by Value
2.4 Global Therapeutic Botulinum Toxin Market by Indication
2.1 Global Migraine Drug Market by Value
2.2 Global Migraine Drug Market by Category
2.3 Global Therapeutic Botulinum Toxin Market by Value
2.4 Global Therapeutic Botulinum Toxin Market by Indication
3. The U.S. Migraine Market
3.1 The U.S. Total Migraine Population
3.2 The U.S. Migraine Population by Diagnosis
3.3 The U.S. Migraine Population with CV Risk Factors
3.4 The U.S Preventive Migraine Treatment by Specialty
3.5 The U.S. Acute Migraine Treated Population by Drug Type
3.6 The U.S. Acute Migraine Prescription Volume
3.7 The U.S. Migraine Drugs Revenue
3.7.1 Cambia
3.7.2 Lasmiditan
3.1 The U.S. Total Migraine Population
3.2 The U.S. Migraine Population by Diagnosis
3.3 The U.S. Migraine Population with CV Risk Factors
3.4 The U.S Preventive Migraine Treatment by Specialty
3.5 The U.S. Acute Migraine Treated Population by Drug Type
3.6 The U.S. Acute Migraine Prescription Volume
3.7 The U.S. Migraine Drugs Revenue
3.7.1 Cambia
3.7.2 Lasmiditan
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Spending on Medicines
4.1.2 Growing Female Population
4.1.3 Increasing Cigarette Consumption
4.1.4 Rising Healthcare Expenditure
4.2 Trends
4.2.1 Emergence of Peripheral Nerve Stimulators
4.2.2 Increased Preference for Non Pharmacological Treatment
4.2.3 Higher Prevalence of Migraine than Other Chronic Diseases
4.2.4 Recurrent Symptoms in Migraine Patients
4.2.5 Drugs under Development for Migraine
4.3 Challenges
4.3.1 Complications associated with Triptans
4.3.2 Treatment Limitations for Patients with Cardiovascular Disease
4.3.3 Rise in Prescription Drugs to OTC Switch
4.1 Growth Drivers
4.1.1 Rising Spending on Medicines
4.1.2 Growing Female Population
4.1.3 Increasing Cigarette Consumption
4.1.4 Rising Healthcare Expenditure
4.2 Trends
4.2.1 Emergence of Peripheral Nerve Stimulators
4.2.2 Increased Preference for Non Pharmacological Treatment
4.2.3 Higher Prevalence of Migraine than Other Chronic Diseases
4.2.4 Recurrent Symptoms in Migraine Patients
4.2.5 Drugs under Development for Migraine
4.3 Challenges
4.3.1 Complications associated with Triptans
4.3.2 Treatment Limitations for Patients with Cardiovascular Disease
4.3.3 Rise in Prescription Drugs to OTC Switch
5. Competitive Landscape
6. Company Profiles
6.1 Amgen Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Teva Pharmaceuticals
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Eli Lilly and Company
6.1 Amgen Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Teva Pharmaceuticals
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Eli Lilly and Company
Comments
Post a Comment